COMMUNIQUÉS West-GlobeNewswire

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update
03/11/2025
Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 [...]
Zelluna ASA – Contemplates private placement
03/11/2025
Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR [...]
Legal Steroids for Bulking, Cutting, Strength from CrazyBulk: Best Selling Legal Steroid Alternatives for Muscle Growth and Bodybuilding in 2025
03/11/2025
Crazy Bulk's Introduces Best Legal Steroid Alternatives Safe and Most Popular Legal Steroids for Muscle Building and Cutting supplements in 2025. It Help to Boost testosterone, and improve muscle growth, strength, and [...]
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
03/11/2025
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, [...]
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
Two oral and seven poster presentations further support the CARVYKTI ® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., [...]
Rendever Receives Nearly $4.5 Million in NIH Funding to Overcome Social Isolation for Older Adults while Supporting Caregivers
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in immersive technology for aging, has secured nearly $4.5 million in grant funding from the National Institutes of Health (NIH) to [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/11/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 novembre 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
03/11/2025
SOMERVILLE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced three presentations of new [...]
Solana Company (NASDAQ: HSDT) Releases Investor Update
03/11/2025
NEWTOWN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced the [...]
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a [...]
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
03/11/2025
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its [...]
BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
03/11/2025
Novel approach designed to address dysregulated RNA splicing events that drive tumor growth and disease progression across multiple hematological malignancies SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BlossomHill [...]
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
03/11/2025
Abstract available on ASH website SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a [...]
March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting
03/11/2025
HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim [...]
NewGen Announces Proposed Reverse Merger with SAXA, Inc. in a $5 Billion Mining Asset Acquisition Deal, Involving Gold, Silver, and Rare Earth
03/11/2025
NewGen will issue 500 million shares at US$10 to acquire the mining assets, substantially boosting shareholders’ equity and transforming the merged entity into a multi-billion-dollar conglomerate BANGKOK, Nov. 03, 2025 [...]
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
03/11/2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Flare Therapeutics to Participate in Upcoming Investor Conferences in November
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
03/11/2025
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in [...]

Pages